Influenza A Clinical Trial
Official title:
Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population
Adopt the design of random, blind method and placebo to parallel control and progressive
methods of groups to study and evaluate the safety and immunogenicity of influenza A (H7N9)
vaccine (two types, one type with two specifications) on people of different ages. The
vaccines used for testing include: influenza A (H7N9) virus inactivated vaccine/split
influenza vaccine (15μg /dose), influenza A (H7N9) virus inactivated vaccine/split influenza
vaccine (30μg / dose), influenza A (H7N9) virus inactivated vaccine/whole influenza vaccine
(7.5μg / dose) and influenza A (H7N9) virus inactivated vaccine/ whole influenza vaccine
(15μg / dose).
The study between different subgroups was carried out in an orderly and progressive manner,
that is, each kind of vaccine by the dose is from low to high according to the order of age
from old to young. Firstly, the study on 15μg/dose split vaccine group (aged 18 and above)
and 7.5μg/dose whole-virus vaccine group (aged 18 and above) was carried out and then the
study on 15μg/dose split vaccine group (aged 12-17) and 7.5μg/dose whole-virus vaccine group
(aged 12-17) was conducted upon 7-day safety was confirmed after the vaccination, finally
the study on 30μg/dose split vaccine group (aged 18 and above) and 15μg/dose whole-virus
vaccine group (aged 18 and above) was done. By that analogy for the same conditions, the
next group of test can be done after the 7-day safety of the last group of vaccine is
confirmed.
Subjects and researchers didn't know the formulations of the vaccines used. The vaccine is
injected into the upper arm deltoid muscle. After 30 minutes of field observation on safety,
the subjects' axillary temperature shall be recorded on the Record Book prepared by the
research and local and systemic reactions to injection at the 6th, 24th, 48th, and 72th hour
and on the 4th, 8th, 21st and 30th day shall also be recorded. This paper collected 5 serum
samples: day 0 (before the first-dose vaccination), day 4 (after the first-dose
vaccination), day 21 (before the second-dose vaccination), day 25 (fourth day after the
second-dose vaccination) and day 42 (21st day after the second-dose vaccination), of which,
blood samples on day 0, 21 and 42 should be stored at 18℃ for antibody detection and the
remaining 2 blood samples are only used for blood routine examination, routine urine test,
blood biochemistry and other laboratory examinations.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03999554 -
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
|
Phase 1 | |
| Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
| Completed |
NCT02487173 -
Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B
|
N/A | |
| Completed |
NCT01701752 -
Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults
|
Phase 1 | |
| Enrolling by invitation |
NCT03207152 -
Biomarkers Predicting Infectivity in an Experimental Human Influenza Model
|
Phase 1 | |
| Terminated |
NCT05567783 -
A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
|
Phase 2 | |
| Not yet recruiting |
NCT00987012 -
The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients
|
N/A | |
| Not yet recruiting |
NCT05928507 -
FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
|
||
| Completed |
NCT03651544 -
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
|
Phase 1 | |
| Completed |
NCT02623322 -
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults
|
Phase 2 | |
| Recruiting |
NCT06160531 -
Influenza Viral Challenge Study of CC-42344 in Healthy Participants
|
Phase 2 | |
| Recruiting |
NCT06191393 -
SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
|
N/A | |
| Completed |
NCT06127108 -
Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel
|
N/A | |
| Completed |
NCT05163730 -
Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel
|
N/A | |
| Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
| Recruiting |
NCT04896853 -
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
|
Phase 1 | |
| Not yet recruiting |
NCT05787444 -
Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
|
||
| Completed |
NCT05354115 -
Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.
|
N/A | |
| Completed |
NCT02014870 -
Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT05897515 -
LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia
|
N/A |